NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Large Increase in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a large growth in short interest in February. As of February 27th, there was short interest totaling 503,652 shares, a growth of 28.5% from the February 12th total of 392,037 shares. Approximately 3.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 182,266 shares, the days-to-cover ratio is presently 2.8 days. Based on an average daily trading volume, of 182,266 shares, the days-to-cover ratio is presently 2.8 days. Approximately 3.7% of the shares of the stock are sold short.

NeuroSense Therapeutics Price Performance

NASDAQ NRSN traded down $0.05 during mid-day trading on Monday, reaching $0.81. 1,205,549 shares of the company’s stock traded hands, compared to its average volume of 139,381. The company has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.02. NeuroSense Therapeutics has a 1-year low of $0.68 and a 1-year high of $2.60.

Institutional Trading of NeuroSense Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in NRSN. Two Sigma Investments LP acquired a new position in NeuroSense Therapeutics in the third quarter worth about $26,000. Jane Street Group LLC bought a new stake in shares of NeuroSense Therapeutics in the second quarter worth about $54,000. Yorkville Advisors Global LP acquired a new stake in shares of NeuroSense Therapeutics in the 4th quarter valued at about $77,000. Finally, Squarepoint Ops LLC lifted its position in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares in the last quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

Analysts Set New Price Targets

NRSN has been the subject of a number of analyst reports. Roth Mkm began coverage on NeuroSense Therapeutics in a research note on Tuesday, March 10th. They set a “buy” rating and a $3.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 29th. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NeuroSense Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.